Sareum hails safety profile for SDC-1801 after phase 1 trial
Sareum Holdings PLC on Thursday said SDC-1801 has the potential to achieve therapeutically effective dose levels with no serious adverse events, following a phase 1 trial. Shares in Sareum rose 7.3%...